Article
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2005
van der Heijden Michiel S, Brody Jonathan R, Dezentje David A, Gallmeier Eike, Cunningham Steven C, Swartz Michael J, DeMarzo Angelo M, Offerhaus G Johan A, Isacoff William H, Hruban Ralph H, Kern Scott E
Abstract excerpt
PURPOSE: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. EXPERIMENTAL DESIGN: Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.